01:12 PM EDT, 06/30/2025 (MT Newswires) -- Artelo Biosciences ( ARTL ) said Monday its first-in-human study of its non-opioid analgesic ART26.12 affirmed the "promising" safety and pharmacokinetic profile observed in preclinical trials.

Shares more than doubled as intraday trading volume catapulted to over 24.5 million from a daily average of about 73,000.

HC Wainwright upgraded Vor Biopharma ( VOR ) to a buy rating from neutral, with a price target of $3.

Shares surged 52%, with trading volume of over 52.9 million against a daily average of about 12.6 million.

Klotho Neurosciences ( KLTO ) said it is progressing with manufacturing and process development work for trials of KLTO-202, its gene therapy candidate for amyotrophic lateral sclerosis.

Shares advanced 61% as intraday trading volume soared to over 124.1 million from a daily average of about 39.2 million.

Price: 14.08, Change: +7.30, Percent Change: +107.67